Evaluation of LB in THA

OSF Healthcare System173 enrolled

Overview

This study aims to compare the effectiveness of liposomal bupivacaine (LB) versus standard of practice local injection containing plain bupivacaine.

Investigation of liposomal bupivacaine to determine if this drug is a valid alternative to standard of care local anesthesia based on evaluation in total hip arthroplasty This is a retrospective cohort study of consecutive patients undergoing THA at 3 hospitals within a U.S. healthcare system from January 2013 to July 2016. The control group received the standard of care undergoing THA (plain bupivacaine or ropivacaine), while the LB group received a mixture containing this drug as the alternative to the standard care. The outcome variables include hospital length of stay, readmissions, total hospital costs, patient pain scores, discharge disposition, morphine equivalent opioid consumption, and postoperative patient ambulation. Generalized linear models were employed to examine aforementioned outcomes controlling for age, gender, race, BMI, alcohol use, tobacco use, and surgeons..

Study Type

OBSERVATIONAL

Enrollment

173

Conditions

Hip Disease

Interventions

Bupivacaine liposomeDRUG

Replace bupivacaine with bupivacaine liposome

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Males or females over the age of 18 * have undergone a THA surgery during the period of interest January 2013 to July 2016). Exclusion Criteria: * excluded from the study based on the following criteria: 1. Concurrent, painful, physical condition or concurrent surgery that may require analgesic treatment in the postoperative period for pain that is not strictly related to the surgical treatment; 2. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder; and 3. Significant renal or hepatic insufficiency.

Outcomes

Primary Outcomes

Comparing physical function of the control group with the experimental group

distance in feet walked

Time frame: 43 months

Comparing length of stay in acute care facility of the control group with the experimental group

number of days

Time frame: 43 months

Comparing total hospital costs of the control group with the experimental group

Number of dollars

Time frame: 43 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.